NET ASSET VALUE – 30 April 2026
On the 30 April 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,478 million and NAV per share was SEK 41.79. Return on NAV per share in the month was -0.26%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.18 | 10.0% |
| Prokarium | 50% | 280 | 3.36 | 8.0% |
| Xspray Pharma | 17% | 217 | 2.60 | 6.2% |
| Empros Pharma | 79% | 204 | 2.46 | 5.9% |
| KAHR Medical | 34% | 199 | 2.39 | 5.7% |
| Atrogi | 44% | 197 | 2.37 | 5.7% |
| Bonsai Biotherapeutics | 100% | 158 | 1.90 | 4.5% |
| Microbiotica | 10% | 125 | 1.51 | 3.6% |
| Xintela | 60% | 122 | 1.47 | 3.5% |
| AnaCardio | 13% | 79 | 0.95 | 2.3% |
| Mendus | 23% | 69 | 0.82 | 2.0% |
| Geneos Therapeutics | 12% | 66 | 0.80 | 1.9% |
| EpiEndo Pharmaceuticals | 9% | 54 | 0.65 | 1.5% |
| Vitara Biomedical | 11% | 52 | 0.63 | 1.5% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.40 | 1.0% |
| Egetis Therapeutics | 1% | 27 | 0.33 | 0.8% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.3% |
| Strike Pharma | 18% | 11 | 0.13 | 0.3% |
| Total | 2,253 | 27.07 | 64.8% | |
| Commercial Growth | ||||
| Symcel | 30% | 204 | 2.46 | 5.9% |
| NorthX Biologics | 61% | 202 | 2.43 | 5.8% |
| Chromafora | 28% | 137 | 1.65 | 4.0% |
| Nanologica | 50% | 86 | 1.03 | 2.5% |
| Frontier Biosolutions | 2% | 26 | 0.31 | 0.8% |
| Bohus Biotech | 45% | 0 | 0.00 | 0.0% |
| Total | 656 | 7.88 | 18.9% | |
| Assets related to Portfolio companies | 204 | 2.45 | 5.9% | |
| Other assets and liabilities | 365 | 4.39 | 10.5% | |
| Net Asset Value | 3,478 | 41.79 | 100.0% | |